In this issue of the Journal, Walensky et al. estimate the benefits that have been gained from multidrug antiretroviral therapies (ARTs) since 1989 [1] . Their finding of ∼3 million years of life saved in the United States quantifies ART benefits at the population level, complementing the well-known data on plummeting US death rates and lower AIDS case report rates noted in the era of potent therapy [2, 3] . The authors' detailed sensitivity analyses, varying key estimated parameters in their models, indicate that less-conservative assumptions generate an estimate of 15 million years of life saved, a plausible "higher-end" estimate of benefit. The typical HIV-infected person now receiving potent combination ART lives at least 13-14 years longer than if he or she were to forego this therapy or if it were otherwise unavailable [1] . Quantifying the survival benefits of expanded diagnosis and modern care suggests that the economic and humanitarian benefits are greater than were hitherto appreciated.
Developing drugs, testing them without undue delay, accelerating their regulatory approval, and making them widely available have saved lives (table 1) . That an average of ∼200,000 persons in the United States have lived an additional year in each of the past 15 years suggests the gift given to those in need from the labor of many [1] . Drugs are discovered and developed by biochemists, pharmaceutical developers, animal modelers, formulation chemists, microbiologists, pharmacologists, and many others in the pharmaceutical industry, in academia, at research institutes, and in government. Drugs are tested for safety and efficacy by clinical-trials experts, research-study nurses, clinical-trials volunteers, community activists, government scientists and science managers, community workers, health-care providers, pharmacists, ethical-review staff, and allied health workers. After drug approval through the work of pharmaceutical companies and regulatory-oversight experts, implementation depends on health-care workers, blood bankers, social workers, mental-health professionals, substanceabuse treatment providers, journalists, science writers, medical editors, spiritual leaders, corporate and small business leaders, enlightened insurers, and family and friends of patients challenged to receive lifelong polypharmacy. (Of course, our public-health workers in health education and promotion, epidemiology, and community prevention efforts are credited, together with community prevention activists, for laboring to reduce the need for these drugs altogether.) Political and policy leaders influence research and care investments even as health activists push the system to be more responsive and efficient. Central to implementation are the HIVinfected persons themselves, who, by the tens of thousands, keep their appointments, take pills, eliminate or reduce highrisk behaviors, and support peers who struggle with the promising but complex world of daily, lifelong therapy. The model of Walensky et al. gives all of us, from our complementary disciplines, cause for celebration.
Zidovudine was the first approved antiretroviral agent, offering benefits that were exciting but, ultimately, only transient, because of the HIV drug resistance resulting from monotherapy [4] [5] [6] [7] [8] . Walensky et al. have assumed a small contribution from Pneumocystis jiroveci prophylaxis but no net benefit from zidovudine monotherapy alone, presumably on the basis of the results of the European Concorde study [8] . Their latter assumption is debatable [6, [9] [10] [11] . Inclusion of survival benefits from zidovudine monotherapy would increase the lives-saved calculus-another conservative bias, in any case. Dual therapy proved to be much superior to monotherapy, and triple therapy was a huge advance, in turn, over the use of 2 drugs [12, 13] . This research progress and its health impact, as documented by Walensky et al., can be seen as a continuum dating from the discovery of the syndrome in 1981 and of the virus in 1983 through the successive approval of each of the 4 drug classes since 1987 (table 1) . This latter-20th-century advance in antiviral therapy has its centennial parallel in the golden era of microbiology and vaccine and drug development in the late 19th and early 20th centuries. Of course, Pasteur, Koch, and their peers were empiricists with little grasp of the microbiology known today [14] ; 21st century grounding in molecular methods augurs well for future discoveries leading to an eventual cure for HIV infection, flushing out and killing virus that is latent in deep tissues. This may be a good time for our national political leaders to reconsider their decision to slow the growth of the budget of the US National Institutes of Health, now lagging behind the rate of inflation [15, 16] .
Use of ART to block HIV transmission from mother to infant has virtually eliminated pediatric HIV infection as a major public-health problem in the United States and other economically prosperous nations [17, 18] . Easier-to-implement nevirapine and nevirapine-zidovudine regimens were developed that could be applied anywhere in the world, as with the "Call to Action" program (sponsored by the Elizabeth Glaser Pediatric AIDS Foundation and the Bill and Melinda Gates Foundation) and the Thai government initiative [19] [20] [21] [22] . Drugs suitable for treating pediatric-age patients with HIV infection are readily available in the United States (table 2) but are less so in resource-limited nations.
In the late 1990s, activists cajoled the pharmaceutical industry into lower drug prices. Combined with lower drug prices due to competition from producers of generic drugs (including in the United States) (table 3), a major effort to provide ART to infected persons in developing countries began through multinational (e.g., the Global Fund to Fight AIDS, Tuberculosis, and Malaria [http://www .theglobalfund.org/en/]), bilateral (e.g., the President's Emergency Program for AIDS Relief [http://www.usaid.gov/our _work/global_health/aids/pepfarfact .html]), and national (e.g., the ahead-ofits-time program in Brazil) initiatives [23, 24] . These are lowering HIV mortality rates in resource-limited settings, just as they did earlier in the economically richer nations [25] . A lethal disease has been transformed into a chronic, manageable condition wherever health services delivery, financing, drug logistics (especially critical in rural areas and developing countries), health manpower, health policy, and health psychology are applied successfully.
Walensky et al. highlight the importance of detecting all persons infected and providing care to all those who know their HIV status [1] . Innovation is needed on many fronts. The state of North Carolina identifies acutely infected, hyperinfectious persons, to provide them with risk-reduction counseling even before antibodies are detectable [26] . Brief health education messages that are designed for clinicians to deliver within the care setting have assisted persons in HIV care to reduce their high-risk behaviors [27] . Practitioners in lower-prevalence regions suggest minimizing pretest counseling through interview-based risk triage, reserving their staff time for the essential posttest counseling sessions [28] . Rapid tests are used widely in developing-world settings to cut costs and avoid the loss to follow-up inherent in an ELISA screening (a result of the inability to provide a same-day result with an ELISA). Rapid tests are an innovation used far less often in the United States than they should be [29] . Antenatal care programs should offer "opt-out" testingthat is, HIV testing that is routine in pregnant women, excluding only those women actively requesting to forego the test [30, 31] . Efforts to increase voluntary counseling and testing and knowledge of HIV status include couples counseling to reduce marital strife and to maximize family-centered care and prevention [32] [33] [34] . These are but a few examples of innovations in the diagnosis, care, and prevention of HIV infection. Drugs that save lives are likely to save society money, because it is cheaper to care for persons with drugs in an outpatient setting than to care for them in intensive care units, acute-care hospital beds, longterm care facilities, and hospices [35] [36] [37] .
Restoring economic productivity and parent-based child care saves so-called indirect costs, and fewer emergency-department visits and hospital stays save direct costs to the health-care system. Further investment in outpatient care should emphasize voluntary counseling and testing programs for HIV diagnosis that are integrated into routine medical care [38] . This must include bridges to care for those infected. The humanitarian benefits are self-evident but may not drive investment as strongly as economic arguments can. Savings may accrue to one provider (e.g., reduced unreimbursed inpatient care expenses to a hospital or lower third-party payments), but costs may be incurred by another source (e.g., Ryan White Care Act funds). Hence, policy makers may see only their costs without knowledge of direct benefits or the savings in a different bailiwick. Early indications are that savings from outpatient management substantially outweigh the costs of the ART-based outpatient treatment programs, both here in the United States and abroad, but good data are scarce [39] .
The millions of life-years saved in the United States should reinvigorate policy debates as to how best to identify HIVinfected persons in our country by offering and encouraging testing as a routine part of medical screening. We must reduce barriers to care, the first of which is the difficulty with which a test is obtained in many venues. We do not require extensive, expensive, time-consuming, and intimidating pretest counseling before screening for diabetes, for example, another disease that is lethal if unmanaged but that is controllable with lifelong medication. Yet many US guidelines demand substantial counseling infrastructures that may discourage primary-care providers from offering HIV tests as easily as they can offer a urine dipstick for glucose to screen for diabetes. Posttest counseling is essential for psychosocial assistance, a bridge to HIV-related health care, and needed to reduce high-risk behaviors, but pretest counseling can be made more efficient to reduce at least one barrier of time and money [28, 38] .
We now face a daunting challenge to do better. From 3 to 5 million personyears of life have been saved for persons living in the United States from 1989 to 2003, but do we know enough about the barriers to prompt diagnosis and effective referral to care? Are we doing enough about those barriers that we do recognize? If we address systematically the barriers to testing, care, and prevention, then future modelers will describe the next 15-year period as having saved hundreds of millions of life-years, not just in North America but around the globe.
